GLYTHERIX LTD.
GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is developing Miltuximab® for the targeted treatment of a number of cancers. At the core of the technology is a protein known as Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian and brain cancers. It is not present in healthy tissue.
GLYTHERIX LTD.
Industry:
Therapeutics
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.glytherix.com
Status:
Active
Contact:
(02) 9850 4000
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Official Site Inspections
http://www.glytherix.com
- Host name: 655191.cloudwaysapps.com
- IP address: 128.199.234.225
- Location: Singapore
- Latitude: 1.314
- Longitude: 103.6839
- Timezone: Asia/Singapore
- Postal: 62
More informations about "GlyTherix Ltd."
Home - GlyTherix
Learn More GlyTherix Therapeutic & Imaging Applications Miltuximab ® Our patented antibodies target human glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, …See details»
GlyTherix Ltd. - Crunchbase Company Profile & Funding
GlyTherix Ltd is an Australian targeted radiotherapy company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. …See details»
Management - GlyTherix
Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and founded three companies. He was a joint recipient of the 2015 Eureka Prize, for …See details»
Board - GlyTherix
Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and has founded three companies. He was joint recipient of the 2015 Eureka Prize, for …See details»
GlyTherix Ltd - LinkedIn
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the …See details»
GlyTherix Company Profile 2024: Valuation, Funding
GlyTherix General Information Description. Operator of an immuno-oncology company intended to develop antibody radiopharmaceuticals for solid tumors. The company specializes in developing therapeutics and patented antibodies …See details»
GLYTHERIX LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GLYTHERIX LTD of MACQUARIE PARK, NEW SOUTH WALES. Get the latest business insights from Dun …See details»
GlyTherix - Overview, News & Similar companies | ZoomInfo.com
GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is developing Miltuximab ® for the …See details»
GlyTherix - Techboard
Jun 9, 2022 GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is …See details»
Glytherix Ltd - Drug pipelines, Patents, Clinical trials - Synapse
About GlyTherix GlyTherix Ltd is an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumors. Miltuximab® specifically targets …See details»
GlyTherix Ltd - amgc.org.au
GlyTherix is an innovative immuno-oncology company recently spun out from its parent company Minomic International Ltd. GlyTherix specialises in cancer therapeutics. We are developing state-of-the-art bio-manufacturing processes with our partners to produce antibody drug products and radio-immunotherapeutic drugs to be tested in clinical trials.See details»
GlyTherix and 3D Imaging Establish Strategic Alliance for ...
Jan 3, 2025 SYDNEY, AUSTRALIA and LITTLE ROCK, AR, January 3, 2025 (Newswire.com) - GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC …See details»
Press Release + Corporate Updates January 10, 2025 - glytherix.com
Press Release GlyTherix to Showcase its targeted radiotherapy technology at JPM Healthcare Week 2025 + Corporate Updates Sydney, Australia – January 10, 2025 – GlyTherix, a leader …See details»
GlyTherix Ltd. - Contacts, Employees, Board Members
Organization. GlyTherix Ltd. Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. GlyTherix Ltd. has 1 …See details»
GlyTherix Establishes its Initial US Development and …
Sep 10, 2024 GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing …See details»
GlyTherix to Partner with SHINE Technologies for Advancing …
Sep 18, 2024 As GlyTherix advances its clinical trials using the medical radioisotope Lu-177, it is building a global supplier network with proximity to major global markets, capable of …See details»
GlyTherix and 3D Imaging Establish Strategic Alliance for ...
Jan 3, 2025 GlyTherix: Dr. Brad Walsh, CEO, +61 413 231 296, [email protected] This press release contains forward-looking statements. Actual results may differ materially from …See details»
GlyTherix And 3D Imaging Establish Strategic Alliance For ...
Jan 3, 2025 GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO) …See details»
GlyTherix and 3D Imaging Establish Strategic Alliance for ...
Jan 3, 2025 SYDNEY, AUSTRALIA and LITTLE ROCK, AR / ACCESSWIRE / January 3, 2025 / GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC …See details»
GlyTherix to Partner with SHINE Technologies for Advancing …
JANESVILLE, WI – September 18, 2024- GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid …See details»